SCHEMBL6173863

SCHEMBL6173863

CC(C)(C)CC(=O)Nc1ccc2c(c1)C=C(C(=O)c1ccccc1N)[N]2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
RAB9A P51151 5/20 0.43
GAA P10253 3/20 0.43
MAPT P10636 1/20 0.43
ADORA2A P29274 3/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
P2RX1 P51575 1/20 0.38
ADORA1 P30542 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
HTT P42858 2/20 0.37
LMNA P02545 1/20 0.37
ECE1 P42892 1/20 0.37
PTGS1 P23219 1/20 0.37
STK17B O94768 1/20 0.37
STK17A Q9UEE5 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6173866 0.81 HPGD (0.55) HPGDMEN1KMT2ARAB9AGAA
SCHEMBL6019178 0.71 ECE1 (0.55) ECE1
SCHEMBL23518557 0.66 HPGD (0.81) HPGDMEN1KMT2ARAB9AGAA
SCHEMBL1947815 0.65 HPGD (0.62) HPGDMEN1KMT2ARAB9AGAA
SCHEMBL23518443 0.65 RAB9A (0.76) HPGDMEN1KMT2ARAB9AGAA
SCHEMBL10888910 0.65 SMN1; SMN2 (0.68) HPGDMEN1KMT2ARAB9AGAA
SCHEMBL3077487 0.65 HPGD (0.54) HPGDMEN1KMT2ARAB9AGAA
SCHEMBL23518425 0.65 HPGD (0.63) HPGDMEN1KMT2ARAB9AGAA
SCHEMBL10891853 0.65 CA1 (0.66) HPGDMEN1KMT2ARAB9AGAA
SCHEMBL4110940 0.64 MAPT (0.86) HPGDMEN1KMT2ARAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432415-B1 SUBSTITUTED 2,5-DIAMIDOINDOLES AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2005-12-28 EP disclosed
EP-1578418-A2 USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES Bayer HealthCare AG (DE) 2005-09-28 EP disclosed
WO-2004056768-A2 USE OF SUBSTITUTED 2,5-DIAMIDOINDOLES FOR THE TREATMENT OF UROLOGICAL DISEASES BAYER HEALTHCARE AG (DE) 2004-07-08 WO disclosed
EP-1432415-A1 SUBSTITUTED 2,5-DIAMIDOINDOLES AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES Bayer HealthCare AG (DE) 2004-06-30 EP disclosed
WO-2003028719-A1 SUBSTITUTED 2,5-DIAMIDOINDOLES AS ECE INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2003-04-10 WO disclosed